Therapeutic inhibition of RAS in non-small cell lung cancer - Takeaways - MDSpire

Therapeutic inhibition of RAS in non-small cell lung cancer

  • By

  • Katherine B. Nichols

  • Benjamin O. Herzberg

  • June 30, 2026

  • 0 min

Share

  • 1

    Oncogenic KRAS mutations are the most common driver event in non-small cell lung cancer (NSCLC), occurring in up to 30% of patients.

  • 2

    The discovery of covalent KRAS G12C inhibitors led to the first FDA accelerated approval for NSCLC treatment in 2021.

  • 3

    Multiple chemotypes targeting KRAS beyond G12C are now in clinical testing, including inhibitors for non-G12C alleles and pan-RAS inhibitors.

  • 4

    The review proposes a classification schema for KRAS-targeting molecules, focusing on their chemical strategies and potential combinations.

  • 5

    KRAS mutations dominate the driver landscape of NSCLC, with approximately 25-30% of lung adenocarcinomas harboring these mutations.

Original Source(s)

Therapeutic inhibition of RAS in non-small cell lung cancer

  • by Katherine B. Nichols, Benjamin O. Herzberg

  • June 30, 2026

Related Content

Development of the glioma imaging complexity score (GICS): a volumetric MRI-based stratification framework

Pagetoid reticulosis (Woringer–Kolopp disease) mimicking eczema: a case report with immunophenotypic analysis and literature review

Advances in the prevention and treatment of radiation-induced brain necrosis: a narrative review